Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Late cornified envelope protein 7A (LCE7A) is a member of the late envelope protein (LEP) family, a cluster of genes in the human epidermal differentiation complex at chromosome 1q21[1][3]. LCE proteins are structural components of the *cornified envelope*, a tough, insoluble layer formed late during epidermal differentiation in keratinocytes, providing an essential part of the skin's protective barrier[1][3]. LCE7A and related LEP family members are incorporated into the envelope at late stages of barrier maturation, after proteins such as loricrin and small proline-rich region proteins, and are substrates for epidermal transglutaminases that catalyze their cross-linking[1][3]. The principal biological role of LCE7A is believed to be the modulation and maintenance of barrier function in skin and other barrier epithelia through structural integration into the cornified envelope[3]. There is currently no evidence that LCE7A is a pharmacological or therapeutic target (such as a receptor, enzyme, transporter, or classical signaling protein), nor are there any known drugs, mechanisms, or biomarker applications related to this protein. Scientific knowledge does not indicate a direct involvement in major disease states, although variants in related LCE proteins may influence skin barrier properties and susceptibility to conditions such as psoriasis; direct clinical or functional data for LCE7A itself are lacking. **Justification for "is_incorrect: true":** - LCE7A is not a therapeutic target, receptor, enzyme, or other druggable protein class. It is a structural protein incorporated into the cornified envelope during terminal keratinocyte differentiation[1][3]. - There is no evidence LCE7A is being targeted by drugs, is used as a biomarker, or is the subject of disease-modifying interventions. - No credible pharmacological or receptor function is assigned to LCE7A. It does not fit standard definitions for a target in drug discovery or therapeutics. **Summary:** LCE7A is a late cornified envelope protein of structural significance in skin differentiation and barrier function, not a druggable target, receptor, or enzyme. No drugs, disease associations, or targeting mechanisms are known for this protein[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Late cornified envelope protein 7A (LCE7A).